SCHEMBL23521965

SCHEMBL23521965

COc1ccc(C)cc1C=N[S@@+]([O-])C(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.41
ALDH1A1 P00352 3/20 0.38
CYP3A4 P08684 1/20 0.38
L3MBTL1 Q9Y468 4/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
LMNA P02545 2/20 0.35
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
GAA P10253 5/20 0.33
USP2 O75604 1/20 0.33
AMY1A P0DUB6 1/20 0.33
MAPT P10636 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
TSHR P16473 2/20 0.33
GFER P55789 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
L3MBTL4 Q8NA19 1/20 0.33
L3MBTL3 Q96JM7 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21723924 1.00 ACHE (0.41) ACHEALDH1A1CYP3A4L3MBTL1SMN1; SMN2
SCHEMBL21723926 1.00 ACHE (0.41) ACHEALDH1A1CYP3A4L3MBTL1SMN1; SMN2
SCHEMBL23521961 1.00 ACHE (0.41) ACHEALDH1A1CYP3A4L3MBTL1SMN1; SMN2
SCHEMBL23522182 0.84 NFE2L2 (0.38) ALDH1A1SMN1; SMN2LMNAGAAMAPT
SCHEMBL23522183 0.84 NFE2L2 (0.38) ALDH1A1SMN1; SMN2LMNAGAAMAPT
SCHEMBL23522173 0.84 KMT2A (0.41) ALDH1A1KMT2AMEN1GAAMAPT
SCHEMBL23522213 0.84 NFE2L2 (0.38) ALDH1A1SMN1; SMN2LMNAGAAMAPT
SCHEMBL23522211 0.84 NFE2L2 (0.38) ALDH1A1SMN1; SMN2LMNAGAAMAPT
SCHEMBL23522180 0.84 NFE2L2 (0.38) ALDH1A1SMN1; SMN2LMNAGAAMAPT
SCHEMBL23522175 0.84 KMT2A (0.41) ALDH1A1KMT2AMEN1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11976059-B2 Isoindolin-1-on derivative, method for preparing same, and pharmaceutical composition comprising same as effective component for preventing or treating cancer KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2024-05-07 US disclosed
EP-3838898-B1 ISOINDOLIN-1-ONE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS AN EFFECTIVE COMPONENT FOR PREVENTING OR TREATING CANCER KOREA RES INST CHEMICAL TECH (KR) 2023-06-07 EP disclosed
US-20210332029-A1 ISOINDOLIN-1-ON DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT FOR PREVENTING OR TREATING CANCER KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2021-10-28 US disclosed
EP-3838898-A1 ISOINDOLIN-1-ON DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT FOR PREVENTING OR TREATING CANCER Korea Research Institute of Chemical Technology (KR) 2021-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210332029-A1 ISOINDOLIN-1-ON DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT FOR PREVENTING OR TREATING CANCER EGFR, TP53, BRCA1 ACHE 2845/4885ALDH1A1 1073/4885CYP3A4 1054/4885
US-11976059-B2 Isoindolin-1-on derivative, method for preparing same, and pharmaceutical composition comprising same as effective component for preventing or treating cancer EGFR, TP53, BRCA1 ACHE 2845/4885ALDH1A1 1073/4885CYP3A4 1054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.